Evaluating the effects of Umifenovir (Arbidol) in COVID-19

Phase 3

Recruiting

Conditions: COVID-19 pneumonia.
COVID-19, virus identified
U07.1

Registration Number: IRCT20151227025726N15

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Laboratory confirmed COVID-19 with RT-PCR
Oxygen saturation < 93%
Fever more than 72 hours before admission
Bilateral pulmonary infiltration
Age over 18 years old

Exclusion Criteria

Chronic kidney disease (Stage IV and V)
Acute kidney injury
Pregnancy or breastfeeding
Drug allergy history
Chronic liver disease (Child pugh C)
Mild phase of COVID-19
Critical phase of COVID-19

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.

Secondary Outcome Measures

Name	Time	Method
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse drug reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At the end of the study. Method of measurement: Medical record.;Need of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record.